Clinical Trials Logo

HER2 Positive Breast Cancers clinical trials

View clinical trials related to HER2 Positive Breast Cancers.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01983501 Completed - Clinical trials for HER2 Positive Breast Cancers

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

Start date: February 28, 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended dose (RD) and to assess the safety and tolerability of tucatinib (ONT-380) combined with ado-trastuzumab emtansine (T-DM1) in patients with HER2+ breast cancer.